VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets..

安大略省沃恩市-（商业线）-博士伦公司（NYSE/TSX:BLCO）是一家领先的全球眼保健公司，致力于帮助人们看到更好的生活，今天宣布已完成收购希德拉（lifitegrast眼科解决方案）5%，专门批准用于治疗干眼症（DED）症状和体征的非类固醇滴眼液，重点关注与干眼症相关的炎症以及某些其他眼科资产。。

In addition to XIIDRA, Bausch + Lomb’s dry eye offering includes eye and contact lens drops from the company’s consumer brand franchises and its pharmaceutical business, including MIEBO™ (perfluorohexyloctane ophthalmic solution), which launched in the United States earlier this month as the first and only FDA-approved prescription eye drop for DED that directly targets tear evaporation..

除了希德拉之外，博士伦公司的干眼产品还包括来自公司消费者品牌特许经营机构及其制药业务（包括MIEBO）的眼药水和隐形眼镜滴剂™ （全氟己基辛烷眼用溶液），本月早些时候在美国推出，作为FDA批准的第一个也是唯一一个直接针对泪液蒸发的DED处方滴眼液。。

“We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb..

“我们希望通过XIIDRA收购和MIEBO推出，迅速在不断增长的处方干眼症类别中占据领先地位，重要的是，帮助目前尚未接受充分治疗干眼症的数百万患者，”主席兼首席执行官Brent Saunders说。博士伦+隆布。。

DED affects approximately 739 million people worldwide, including approximately 38 million people in the United States.1 The prescription U.S. DED field is expected to grow at a double-digit compounded annual growth rate over the next five years.2

DED影响全球约7.39亿人，其中包括美国约3800万人.1处方美国DED领域预计将在未来五年内以两位数复合年增长率增长.2

As part of the transaction, Bausch + Lomb also acquired libvatrep (also known as SAF312), an investigational compound being studied for the treatment of chronic ocular surface pain, and AcuStream™ technology, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye.3,4 Libvatrep is currently in Phase 2b development with study results anticipated to be completed in the second half of 2023..

作为交易的一部分，Bausch+Lomb还收购了libvatrep（也称为SAF312），这是一种正在研究用于治疗慢性眼表疼痛和AcuStream的研究化合物™ 技术，一种研究设备，可能有助于精确给药和准确递送某些局部眼科药物到眼睛.3,4 Libvatrep目前正处于2b期开发阶段，研究结果预计将于2023年下半年完成。。

Transaction Details

交易细节

Under the terms of the agreement, Bausch + Lomb, through an affiliate, acquired XIIDRA and the other ophthalmology assets from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization.

根据协议条款，博士伦通过附属公司从诺华获得希达拉和其他眼科资产高达25亿美元，其中包括预先支付17.5亿美元现金，潜在里程碑义务高达7.5亿美元，基于销售门槛和管道商业化。

Bausch + Lomb also brought on the sales force supporting XIIDRA. The company funded the acquisition with the previously announced offering of $1.4 billion aggregate principal amount of 8.375% senior secured notes due 2028 (“Notes”) and $500 million of new term B loans under an incremental term loan facility (“Term Loan Facility”).

博士伦还带来了支持希德拉的销售人员。该公司通过之前宣布的增量期贷款设施（“期贷款设施”）提供14亿美元的本金额总额8.375%的2028年高级担保债券（“债券”）和5亿美元的新B期贷款来资助此次收购。）。

The issuance of the Notes and the closing of the Term Loan Facility occurred substantially concurrently with the closing of the acquisition..

债券的发行和期贷款设施的关闭与收购结束的同时发生。。

WHAT IS XIIDRA?

XIIDRA是什么？

XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

XIIDRA（lifitegrast眼用溶液）5%是用于治疗干眼病症状和体征的处方滴眼液。

IMPORTANT SAFETY INFORMATION

重要的安全信息

Do not use XIIDRA if you are allergic to any of its ingredients. Seek medical care immediately if you get any symptoms of an allergic reaction.

如果您对任何成分过敏，请勿使用XIIDRA。如果您出现任何过敏反应症状，请立即就医。

The most common side effects of XIIDRA include eye irritation, discomfort or blurred vision when the drops are applied to the eyes, and an unusual taste sensation.

希德拉最常见的副作用包括滴眼液涂抹在眼睛上时的眼睛刺激，不适或视力模糊，以及不寻常的味觉。

To help avoid eye injury or contamination of the solution, do not touch the container tip to your eye or any surface. If you wear contact lenses, remove them before using XIIDRA and wait for at least 15 minutes before placing them back in your eyes.

为帮助避免眼睛受伤或溶液污染，请勿将容器尖端触摸眼睛或任何表面。如果您佩戴隐形眼镜，请在使用XIIDRA之前将其取下并等待至少15分钟，然后再将其放回眼睛中。

It is not known if XIIDRA is safe and effective in children under 17 years of age.

目前尚不清楚希德拉对17岁以下儿童是否安全有效。

Click here for full Prescribing Information for XIIDRA.

点击此处获取XIIDRA的完整处方信息。

WHAT IS MIEBO?

什么是MIEBO？

MIEBO™ (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

米博™ （全氟己基辛烷眼用溶液）用于治疗干眼病的体征和症状。

IMPORTANT SAFETY INFORMATION

重要的安全信息

Patients should remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting.

患者在使用MIEBO前应取下隐形眼镜，并在重新插入前等待至少30分钟。

It is important for patients to use MIEBO exactly as prescribed.

对于患者而言，完全按照规定使用MIEBO非常重要。

It is not known if MIEBO is safe and effective in children under the age of 18.

目前尚不清楚MIEBO对18岁以下儿童是否安全有效。

The most common eye side effect seen in studies was blurred vision (1% to 3% of patients reported blurred vision and eye redness).

研究中最常见的眼部副作用是视力模糊（1%至3%的患者报告视力模糊和眼睛发红）。

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

鼓励患者向FDA报告处方药的不良副作用。访问www.fda.gov/medwatch或致电1-800-fda-1088。

Click here for full Prescribing Information for MIEBO.

点击这里获取MIEBO的完整处方信息。

About Bausch + Lomb

关于Bausch

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.

博士伦致力于保护和增强世界各地数百万人的视力礼物-从出生到生命的每个阶段。其全面的400多种产品组合包括隐形眼镜，镜片护理产品，眼保健产品，眼科药物，非处方产品以及眼科手术器械和器械。

Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram..

博士伦成立于1853年，拥有重要的全球研发，制造和商业足迹，约有13000名员工，并在近100个国家/地区设有。博士伦总部设在安大略省沃恩市，公司总部设在新泽西州布里奇沃特。欲了解更多信息，请访问www.bausch.com并在Twitter，LinkedIn，Facebook和Instagram上与我们联系。。

Bausch + Lomb Forward-looking Statements

博士伦+伦布前瞻性声明

This news release may contain forward-looking statements, including, but not limited to, the anticipated impact of the transaction, including our anticipated stake in the dry eye field. Forward-looking statements may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions.

本新闻稿可能包含前瞻性声明，包括但不限于交易的预期影响，包括我们预期的干眼领域股份。前瞻性陈述通常可以通过使用“预期”，“希望”，“期望”，“意图”，“计划”，“应该”，“可以”，“将会”，“将会”，“可能”，“相信”，“估计”，“潜力”，“目标”或“继续”以及变体或类似表达方式。

These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S.

这些声明基于当前对管理层的期望和信念，并且存在某些风险和不确定性，可能导致实际结果与前瞻性声明中描述的结果大不相同。这些风险和不确定性包括但不限于博士伦与美国的文件中讨论的风险和不确定性。

Securities and Exchange Commission and the Canadian Securities Administrators (including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, and its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2022), which factors are incorporated herein by reference. In addition, such risks and uncertainties include, but are not limited to, the following: the effect of the announcement or closing of the Transaction on the market price of Bausch + Lomb’s common stock and Bausch + Lomb’s ability to maintain relationships with customers, suppliers, other business partners or governmental entities; the impact of the Transaction on Bausch + Lomb’s business, financial position and results of operations, including with respect to expectations regarding margin expansion, accretion and deleveraging; the possibility that the expected benefits of the Transaction will not be realized or will not be realized within the e.

证券交易委员会和加拿大证券管理人员（包括其季度10-Q表格的季度报告，截至2023年6月30日，其财年10-K表格的年度报告截至2022年12月31日），哪些因素通过引用并入本文。此外，这些风险和不确定性包括但不限于以下内容：交易公告或结案对博士伦普通股市场价格的影响以及博士伦与客户，供应商，其他业务伙伴或政府实体；交易对博士伦公司业务，财务状况和经营成果的影响，包括对保证金扩张，吸积和删除的预期；交易的预期收益不会实现或不会在e内实现的可能性。

References

工具书类

Downs P. 2020 Dry Eye Products Market Report: A Global Analysis for 2019 to 2025. Market Scope; 2020.

Downs P.2020干眼产品市场报告：2019年至2025年的全球分析。市场范围；2020.

U.S. dry-eye size including aqueous supplements, secretagogues, corticosteroids, LFA-1 antagonists, calcineurin inhibitors across anti-inflammatory and non-anti-inflammatory drug classes. Source: DRG (12/2022); Expert interviews; Analyst reports.

U、 S.干眼大小，包括水性补充剂，促分泌素，皮质类固醇，LFA-1拮抗剂，抗炎和非抗炎药物类别的钙调神经磷酸酶抑制剂。资料来源：DRG（12/2022）；专家访谈；分析师报告。

Quiroz-Mercado H, Ivri E, Gonzalez-Salinas R, et al. Clinical evaluation of a novel electromechanical topical ocular drug delivery system: two phase 1 proof of concept studies. Clin Ophthalmol. 2020;14:139-147.

Quiroz-Mercado H，Ivri E，Gonzalez-Salinas R等人。新型机电局部眼部给药系统的临床评估：两项1期概念验证研究。Clin Ophthalmol。2020;14:139-147.

Data on file. AcuStream repetitive acute and real-time delivery study. Novartis, 2022.

数据在文件中。AcuStream重复急性和实时递送研究。诺华，2022年。

© 2023 Bausch + Lomb.

© 2023 Bausch Lomb。